Showing 4891-4900 of 20470 results for "".
- AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groupshttps://reachmd.com/news/aad-2026-relabotulinumtoxina-shows-consistent-efficacy-across-age-groups/2486431/A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data
- AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenationhttps://reachmd.com/news/lumenis-launches-trilift-20-for-combined-muscle-and-skin-rejuvenation/2486430/Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address
- Diverse UCLA Biobank Reveals New Genetic Links to Disease Risk and Drug Responsehttps://reachmd.com/news/diverse-ucla-biobank-reveals-new-genetic-links-to-disease-risk-and-drug-response/2486405/The report on the UCLA ATLAS Community Health Initiative describes analyses of linked genetic data and electronic health records that co
- AD-VISE: Better Patient Outcomes Tied to Achieving MDA at 6 Months with Upadacitinibhttps://reachmd.com/news/ad-vise-better-patient-outcomes-tied-to-achieving-mda-at-6-months/2486433/Patients with atopic dermatitis (AD) treated with upadacitinib who achieved minimal disease activity (MDA) demonstrated markedly improved patient-reported outcomes (PROs) compared with those meeting moderate or no treatment targets, according to findings from the r
- NDM‑1–carrying Acinetobacter in Hospital Wastewater: Genomic Findings from Shenzhenhttps://reachmd.com/news/ndm1carrying-acinetobacter-in-hospital-wastewater-genomic-findings-from-shenzhen/2486402/A culture-based genomic survey of pre-disinfection hospital wastewater from Shenzhen, China, reports recovery of carbapenem-resistant Acinetobacter isola
- Rezpegaldesleukin Shows Promise in Alopecia Areata in Phase 2b Trialhttps://reachmd.com/news/rezpegaldesleukin-shows-promise-in-alopecia-areata-in-phase-2b-trial/2486426/Rezpegaldesleukin, an IL-2 pathway agonist designed to expand regulatory T cells (Tregs), demonstrated clinical efficacy and a favorable safety profile in patients with severe-to-very-severe alopecia areata (AA), according to Phase 2b REZOLVE-AA data presented by David Rosmarin, MD, at the Americ
- Zumilokibart Shows Rapid Symptom Relief in Atopic Dermatitishttps://reachmd.com/news/zumilokibart-shows-rapid-symptom-relief-in-atopic-dermatitis/2486425/Zumilokibart (APG777), a half-life–extended anti–IL-13 monoclonal antibody, demonstrated rapid and sustained improvements in symptoms and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to Phase 2 APEX Part A results presented by Emma Guttman-Yassky, MD, PhD,
- AAD Updates Systemic Therapy Guidelines for Adult ADhttps://reachmd.com/news/aad-updates-systemic-therapy-guidelines-for-adult-atopic-dermatitis/2486418/The American Academy of Dermatology (AAD) has issued an interim update to its clinical practice guidelines for systemic treatment of moderate to severe atopic dermatitis (AD) in adults, reflecting the rapid expansion of evidence supporting targeted therapies. The u
- Amlitelimab Shows Efficacy Across Phase 3 AD Trialshttps://reachmd.com/news/amlitelimab-shows-efficacy-across-phase-3-ad-trials/2486422/Late-breaking Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting demonstrated that amlitelimab, a nondepleting anti–OX40 ligand (OX40L) antibody, significantly improved disease severity and symptoms in patients with moderate-to-severe atopic dermatitis (AD), b
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://reachmd.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee